What is a Clinical Trial?

A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the fastest and safest way to find treatments that are effective in human subjects.

Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.

Clinical trials are ongoing and some may not be listed. If you have any questions please email the CHI Health Research office or call 402-343-8511.

Condition Description Disease Site
ACS Dal-GenE MHICC 2050 (Ref number:192)

Study Title:Double blind, randomized, placebo controlled, parallel group study to assess the effects of study drug on reducing the occurrence of major cardiovascular events in pts with acute coronary syndrome.A phase III, double-­-blind, randomized placebo-­-controlled study to evaluate the effects of dalcetrapib on cardiovascular CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-­-GenE trial

Heart
Dementia IDEAS (Ref number:202)

We are assessing the impact of performing amyloid PET scans on outcomes of patients with early dementia

Brain
Gastroenterology Humira Legacy (Ref number:175)

Registry looking for patients with moderate to severe active ulcerative colitis who receive Humira with or without immunomodulatory therapy.

Colon
Heart Attacks/Stroke CIRT (Ref number:186)

We are investigating whether an oral drug, methotrexate can reduce risk of heart attacks, stroke, or death in patients with type 2 diabetes or metabolic syndrome who have already had at least one heart attack or have major blockages in more than one coronary artery found on a heart catheterization.

Heart
Heart Failure Heart FID (Ref number:182)

We are investigating whether an intravenous (IV) drug used for the treatment of anemia can improve symptoms in patients with heart failure.

Heart
Heart Failure VICTORIA (Ref number:194)

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA). Site number 2526

Heart
Heavy Menstrual Bleeding LIBERTY1-Myovant (Ref number:203)

We are investigating the effects of an oral drug on patients with heavy menstrual bleeding associated with uterine fibroids.

Ovary
Kidney Disease FIGARO (Ref number:188)

A Randomized, Double-blind, placebo-controlled, parallel-group, multicenter, event driven Phase 3 study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitis and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

Kidney
Kidney Disease FIDELIO-DKD 16244 (Ref number:187)

We are investigating the safety and efficacy of a new oral drug to find out if it can offer protection against further worsening of your kidney disease as well as heart disease or stroke.

Kidney
Kidney Disease Akebia (Ref number:195)

Protocol AKB-6548-CI-0014: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT – CORRECTION) Protocol AKB-6548-CI-0015: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT – CONVERSION)

Kidney
Liver Disease NASH 747-303 REGENERATE (Ref number:204)

Nonalcoholic steatohepatitis is when the liver is swollen and damaged from the build up of fat in the liver. We are investigating the safety and efficacy of an oral drug to delay health-related conditions in patients with nonalcoholic steatohepatitis or evidence of liver fibrosis (damaged or scarred liver tissue).

Liver